Press releases
- Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
- Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
- Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
- Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
- Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
- Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
- Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
- Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
More ▼
Key statistics
On Wednesday, Ligand Pharmaceuticals Inc (LGNXZ:PKC) closed at 0.0096, -43.53% below its 52-week high of 0.017, set on Jun 07, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.0011 |
---|---|
High | 0.0096 |
Low | 0.0011 |
Bid | -- |
Offer | -- |
Previous close | 0.0096 |
Average volume | 15.62k |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of May 01 2024 18:03 BST.
More ▼